Global Information
회사소개 | 문의 | 비교리스트

전게놈 및 엑솜 시퀀싱 시장 : 용도별, 생물별, 제품별(2022-2026년)

WHOLE GENOME and EXOME SEQUENCING MARKETS, By Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2022 to 2026 "

리서치사 Howe Sound Research
발행일 2021년 11월 상품 코드 1036269
페이지 정보 영문 596 Pages
가격
US $ 6,995 ₩ 8,411,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 12,620,000 PDF (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 16,828,000 PDF (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



전게놈 및 엑솜 시퀀싱 시장 : 용도별, 생물별, 제품별(2022-2026년) WHOLE GENOME and EXOME SEQUENCING MARKETS, By Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2022 to 2026 "
발행일 : 2021년 11월 페이지 정보 : 영문 596 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 전게놈 및 엑솜 시퀀싱 시장에 대해 조사했으며, 시장의 개요와 용도별, 생물별, 제품별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 시장 가이드

  • 전게놈 시퀀싱 시장 - 전략적 상황 분석과 COVID의 영향
  • 이그제큐티브, 마케팅, 세일즈, 비지니스 개발 스탭을 위한 가이드
  • 경영 컨설턴트 및 투자 고문을 위한 가이드

제2장 서론과 시장의 정의

  • 본 보고서에서 전게놈 시퀀싱의 정의
  • 게노믹스 혁명
  • 시장의 정의
  • 전망 : 헬스케어, IVD 산업 및 COVID-19 팬데믹
  • 게놈의 사이징
  • 설치 기반 하이스루풋(HIGH THROUGHPUT) 시퀀싱 시설 리스트

제3장 시장 개요

  • 시장 참가 기업은 다양한 역할을 담당한다.
    • 기기 제조업체
    • 전문·독립계 시험기관
    • 독립계국·지역의 시험기관
    • 독립계 시험기관 분석
    • 공립 국립/지역 연구소
    • 병원 검사실
    • 임상 검사실
    • DTC 시험기관
    • 시퀀싱 시험기관
    • 감사 기관
  • 전게놈 시퀀싱 - 시장, 예, 인사이트
  • 업계 구조

제4장 시장 동향

  • 성장 촉진요인
    • 진단 요인
    • 코드의 해석
    • 농업의 변화
    • 불임 치료 기술의 시대
    • 병원체의 과제
  • 성장 억제요인
    • 경쟁 격화에 의한 가격 하락
    • 저비용
    • 헬스케어비의 우려가 성장을 억제
    • 웰니스의 결점
    • GMO 반대 운동
  • 시퀀싱 장비

제5장 WGES의 최근 개발

제6장 주요 기업의 개요

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioM?rieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gencove
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health(Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health(GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

제7장 세계의 전게놈 및 엑솜 시퀀싱 시장

  • 세계 시장 개요, 국가별
  • 세계 시장 - 개요, 용도별
  • 세계 시장 - 개요, 생물별
  • 세계 시장 - 개요, 제품별

제8장 세계의 전게놈 및 엑솜 시퀀싱 시장 - 용도별

  • 연구
  • 임상의 인간
  • 임상의 종양
  • 임상의 병원체
  • D2C
  • 농업/기타

제9장 세계의 전게놈 및 엑솜 시퀀싱 시장 - 생물별

  • 인간
  • 병원체
  • 기타

제10장 세계의 전게놈 및 엑솜 시퀀싱 시장 - 제품별

  • 장비
  • 시약
  • 분석
  • 소프트웨어 및 기타

제11장 전게놈 및 엑솜 시퀀싱의 미래 비전

제12장 부록

KSA 21.11.22

Table of Tables

  • Table 1 Leading Genomic Companies Revenue Growth (USD $M)
  • Table 2 The Base Pairs
  • Table 3 Most Common Traditional Genetic Disorders
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Whole Genome Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 Roles of WGS in AgriBio
  • Table 9 The Factors Driving Growth
  • Table 10 Factors Limiting Growth
  • Table 11 - Listing of Current NGS Instrument Specifications
  • Table 12 Six New Sequencing Technologies
  • Table 13 - Global Market by Region
  • Table 14 Global Market by Application
  • Table 15 Global Market by Organism
  • Table 16 Global Market by Product
  • Table 17 Research by Country
  • Table 18 Clinical Human by Country
  • Table 19 Clinical Tumor by Country
  • Table 20 Clinical Pathogen by Country
  • Table 21 Direct to Consumer by Country
  • Table 22 Agriculture/Other by Country
  • Table 23 Human by Country
  • Table 24 Pathogen by Country
  • Table 25 Other Organism by Country
  • Table 26 Instruments by Country
  • Table 27 Reagents by Country
  • Table 28 Analysis by Country
  • Table 29 Software & Other by Country
  • Table 30 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Relative Growth of Select Genomic Companies
  • Figure 2 Size of Genome for Various Species
  • Figure 3 - Cost To Sequence a Human Genome
  • Figure 4 Base Year Country Market Share Chart
  • Figure 5 Global Market by Application - Base vs. Final Year
  • Figure 6 Global Market by Application Base Year
  • Figure 7 Global Market by Application Final Year
  • Figure 8 Application Type Share by Year
  • Figure 9 by Application Segment Growth
  • Figure 10 by Organism - Base vs. Final Year
  • Figure 11 by Organism Market Base Year
  • Figure 12 by Organism Market Final Year
  • Figure 13 by Organism Share by Year
  • Figure 14 by Organism Segment Growth
  • Figure 15 by Product - Base vs. Final Year
  • Figure 16 by Product Market Base Year
  • Figure 17 by Product Market Final Year
  • Figure 18 by Product Share by Year
  • Figure 19 by Product Segment Growth
  • Figure 20 Research Growth
  • Figure 21 Clinical Human Growth
  • Figure 22 Clinical Tumor Growth
  • Figure 23 Clinical Pathogen Growth
  • Figure 24 Direct to Consumer Growth
  • Figure 25 Agriculture/Other Growth
  • Figure 26 Human Growth
  • Figure 27 Pathogen Growth
  • Figure 28 Other Organism Growth
  • Figure 29 Instruments Growth
  • Figure 30 Reagent Growth
  • Figure 31 Analysis Growth
  • Figure 32 Software & Other Growth

OVERVIEW:

The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer related activity has suffered. Find out all about it in the comprehensive report of Whole Genome Sequencing. The complete genome of the COVID virus is included as an example of the work being done.

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Whole Genome Sequencing Market - Strategic Situation Analysis & COVID Impact
    • 1.1.1 Selected Genetic Testing Companies Revenue & Growth
    • 1.1.2 Selected Companies Growth Chart
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 Whole Genome Sequencing Definition In This Report
    • 2.1.1 Whole and Exome Sequencing
    • 2.1.2 Research and Clinical
    • 2.1.3 Clinical Tumor
    • 2.1.4 Clinical Pathogen
    • 2.1.5 Agri/Other
    • 2.1.6 Direct to Consumer
  • 2.2 The Genomics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.4.1 Global Healthcare Spending
    • 2.4.2 Spending on Diagnostics
    • 2.4.3 Important Role of Insurance for Diagnostics
  • 2.5 Sizing the Genome - Not What You Think
    • 2.5.1 Cost, Price and Genome Size, Pricing Practice
  • 2.6 GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

3 Market Overview

  • 3.1 Market Participants Play Different Roles
    • 3.1.1 Instrument Manufacturer
    • 3.1.2 Independent lab specialized/esoteric
    • 3.1.3 Independent lab national/regional
    • 3.1.4 Independent lab analytical
    • 3.1.5 Public National/regional lab
    • 3.1.6 Hospital lab
    • 3.1.7 Physician lab
    • 3.1.8 DTC Lab
    • 3.1.9 Sequencing Labs
    • 3.1.10 Audit body
  • 3.2 Whole Genome Sequencing -Markets, Examples and Discussion
    • 3.2.1 Direct to Consumer - Two Approaches
      • 3.2.1.1 The New Age of Medical Information
      • 3.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
      • 3.2.1.3 Newborn and Prenatal - A Brave New World
      • 3.2.1.4 DTC - How Many Segments?
    • 3.2.2 Research Markets
      • 3.2.2.1 Research Funding and Capital Expense
      • 3.2.2.2 WGS Datasets Preferred
      • 3.2.2.3 Existing research repurposed
      • 3.2.2.4 Organism Wide Market
      • 3.2.2.5 Service Suppliers Respond
    • 3.2.3 Clinical - Understanding Germline and Somatic
      • 3.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
    • 3.2.4 Pathogen Testing
      • 3.2.4.1 The Hepatitis C Story
      • 3.2.4.2 Will the Microbiology Department Disappear?
    • 3.2.5 AgriBio - Big Business
      • 3.2.5.1 GMO is Here to Stay
      • 3.2.5.2 WGS Benefits and Risks
      • 3.2.5.3 The New Agriculture
  • 3.3 Industry Structure
    • 3.3.1 Hospital's Testing Share
    • 3.3.2 Economies of Scale
    • 3.3.3 Instrument Manufacturer Role
    • 3.3.4 Healthcare Industry Impacts - Still Struggling
      • 3.3.4.1 Can the Healthcare Industry Adapt?
      • 3.3.4.2 Genetic Counselling as an Industry
      • 3.3.4.3 WGES Adoption and Cannibalization
      • 3.3.4.4 The Meaning of Grail

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Diagnostic Factors
    • 4.1.2 Interpreting the Code Otherwise
    • 4.1.3 Changes in Agriculture
    • 4.1.4 Fertility Technology Comes of Age
    • 4.1.5 Pathogen Challenges
  • 4.2 Factors Limiting Growth
    • 4.2.1 Increased Competition Lowers Price
    • 4.2.2 Lower Costs
    • 4.2.3 Healthcare Cost Concerns Curtail Growth
    • 4.2.4 Wellness has a downside
    • 4.2.5 GMO Opposition Movement
  • 4.3 Sequencing Instrumentation
    • 4.3.1 Instrumentation Tenacity
    • 4.3.2 Declining Cost Changes Industry Structure
    • 4.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
    • 4.3.4 Illumina
    • 4.3.5 ION
    • 4.3.6 Pacific Biosystems
    • 4.3.7 Roche 454
    • 4.3.8 SOLiD
    • 4.3.9 Oxford Nanopore
      • 4.3.9.1 What is Oxford Nanopore Sequencing?
      • 4.3.9.2 What can Oxford Nanopore Sequencingt be used for?
      • 4.3.9.3 Oxford Nanopore Products
    • 4.3.10 Long Reads - Further Segmentation
    • 4.3.11 Linked Reads
    • 4.3.12 Targeted Sequencing Adopts CRISPR
    • 4.3.13 New Sequencing Technologies
      • 4.3.13.1 RNAP sequencing
      • 4.3.13.2 In vitro virus high-throughput sequencing
      • 4.3.13.3 Tunnelling currents DNA sequencing
      • 4.3.13.4 Sequencing by hybridization
      • 4.3.13.5 Sequencing with mass spectrometry
      • 4.3.13.6 Microfluidic Sanger sequencing
      • 4.3.13.7 Microscopy-based techniques

5 WGES Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 GenomSys Gains CE Mark for New Genomic Analysis Software
  • 5.3 WGS Finds Lung Cancers Fall Into Molecular Subtypes
  • 5.4 Testing Distinguishes Benign Tumors From Precancerous Condition
  • 5.5 Plan to Sequence All Newborns in UK
  • 5.6 Clear Labs Raises $60M for Nanopore Sequencing
  • 5.7 Variantyx Expands Into Prenatal, Cancer Testing
  • 5.8 Whole-Genome Sequencing Aids Diagnosis in Stockholm
  • 5.9 Variantyx Raises $20M
  • 5.10 Nonacus WGS Service for SARS-CoV-2 Laboratories
  • 5.11 Center to Report Risk Scores in Clinical WGS
  • 5.12 Stanford Launches WGS for Cardiovascular Testing
  • 5.13 Illumina and NY Healthcare Partner on Clinical WGS
  • 5.14 Increased Adoption of WGS Needs Acceptance by Payors, Providers
  • 5.15 Veritas Intercontinental Completes €5M Series B Financing Round
  • 5.16 M2GEN and Discovery Life Sciences in Bioinformatics Agreement
  • 5.17 Genomics England Adopts Quantum ActiveScale Object Storage
  • 5.18 GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
  • 5.19 NHS Wales Introduces WGS for Critically Ill Newborns
  • 5.20 Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
  • 5.21 C2i Genomics to Launch Trials for MRD Detection Tech
  • 5.22 Roche Acquires Sequencing Company Stratos Genomics
  • 5.23 UK COVID-19 Sequencing Consortium Launches
  • 5.24 Invitae Acquires Three Companies: YouScript, Genelex, Diploid
  • 5.25 Experience From Centralized Genomic Medicine Lab
  • 5.26 MGI to Enable $100 Human Genome
  • 5.27 Nebula Genomics offers $299 WGS
  • 5.28 Team to Study Campylobacter Omics
  • 5.29 Veritas Genetics Restarts US Business
  • 5.30 NEOGEN, Gencove partner to advance animal genomics
  • 5.31 UK Whole-Genome Sequencing Project Obtains £200M
  • 5.32 WGS may help with disease outbreaks
  • 5.33 Veritas Cuts WGS Price by 40%
  • 5.34 Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
  • 5.35 Machine-learning system used to diagnose genetic diseases
  • 5.36 Whole Genome Sequencing for healthy creates controversy
  • 5.37 Nebula Genomics Offers FREE Whole Genome Sequencing

6 Profiles of Key Companies

  • 6.1 10x Genomics, Inc.
  • 6.2 23andME Inc.
  • 6.3 Abbott Diagnostics
  • 6.4 AccuraGen Inc.
  • 6.5 Adaptive Biotechnologies
  • 6.6 Admera Health, LLC
  • 6.7 Agena Bioscience, Inc.
  • 6.8 Agilent
  • 6.9 Akonni Biosystems
  • 6.10 Ancestry.com LLC
  • 6.11 Anchor Dx
  • 6.12 ArcherDx, Inc.
  • 6.13 ARUP Laboratories
  • 6.14 Asuragen
  • 6.15 Baylor Miraca Genetics Laboratories
  • 6.16 Beckman Coulter Diagnostics
  • 6.17 Becton, Dickinson and Company
  • 6.18 BGI Genomics Co. Ltd
  • 6.19 Bioarray Genetics
  • 6.20 Biocept, Inc.
  • 6.21 Biodesix Inc.
  • 6.22 BioFluidica
  • 6.23 BioGenex
  • 6.24 Biolidics Ltd
  • 6.25 bioMérieux Diagnostics
  • 6.26 Bioneer Corporation
  • 6.27 Bio-Rad Laboratories, Inc
  • 6.28 Bio-Techne
  • 6.29 C2i Genomics
  • 6.30 Cancer Genetics
  • 6.31 Caris Molecular Diagnostics
  • 6.32 CellMax Life
  • 6.33 Centogene
  • 6.34 Chronix Biomedical
  • 6.35 Circulogene
  • 6.36 Clear Labs
  • 6.37 Clinical Genomics
  • 6.38 Complete Genomics, Inc. - A BGI Company
  • 6.39 Cynvenio
  • 6.40 Dante Labs
  • 6.41 Datar Cancer Genetics Limited
  • 6.42 Day Zero Diagnostics
  • 6.43 Diasorin S.p.A.
  • 6.44 Epic Sciences
  • 6.45 Epigenomics AG
  • 6.46 Eurofins Scientific
  • 6.47 Excellerate Bioscience
  • 6.48 Exosome Diagnostics
  • 6.49 Fabric Genomics
  • 6.50 Fluidigm Corp
  • 6.51 Freenome
  • 6.52 FUJIFILM Wako Diagnostics
  • 6.53 Fujirebio
  • 6.54 Fulgent Genetics
  • 6.55 GE Global Research
  • 6.56 GE Healthcare Life Sciences
  • 6.57 Gencove
  • 6.58 Genedrive
  • 6.59 GeneFirst Ltd.
  • 6.60 Genetron Health (Beijing) Co., Ltd.
  • 6.61 Genewiz
  • 6.62 Genomic Health
  • 6.63 Genomics England
  • 6.64 Genomics Personalized Health (GPH)
  • 6.65 GenomOncology
  • 6.66 Genzyme Corporation
  • 6.67 Grail, Inc.
  • 6.68 Grifols
  • 6.69 Guardant Health
  • 6.70 Guardiome
  • 6.71 HeiScreen
  • 6.72 Helix
  • 6.73 Helomics
  • 6.74 Hologic
  • 6.75 Horizon Discovery
  • 6.76 HTG Molecular Diagnostics
  • 6.77 Human Longevity, Inc.
  • 6.78 iCellate
  • 6.79 Illumina
  • 6.80 Incell Dx
  • 6.81 Inivata
  • 6.82 Invitae Corporation
  • 6.83 Invivoscribe
  • 6.84 Karius
  • 6.85 Macrogen
  • 6.86 MDNA Life SCIENCES, Inc.
  • 6.87 MDx Health
  • 6.88 Medgenome
  • 6.89 Meridian Bioscience
  • 6.90 Mesa Biotech
  • 6.91 MIODx
  • 6.92 miR Scientific
  • 6.93 MNG Labs
  • 6.94 Molecular MD
  • 6.95 NantHealth, Inc.
  • 6.96 Natera
  • 6.97 Nebula Genomics
  • 6.98 NeoGenomics
  • 6.99 New Oncology
  • 6.100 Novogene Bioinformatics Technology Co., Ltd.
  • 6.101 Omega Bioservices
  • 6.102 OncoDNA
  • 6.103 OpGen
  • 6.104 ORIG3N, Inc.
  • 6.105 Origene Technologies
  • 6.106 Oxford Nanopore Technologies
  • 6.107 Panagene
  • 6.108 Perkin Elmer
  • 6.109 Personal Genome Diagnostics
  • 6.110 Personalis
  • 6.111 Precipio
  • 6.112 PrecisionMed
  • 6.113 Promega
  • 6.114 Protagen Diagnostics
  • 6.115 Qiagen Gmbh
  • 6.116 Quantumdx
  • 6.117 Regeneron
  • 6.118 Roche Molecular Diagnostics
  • 6.119 Roswell Biotechnologies
  • 6.120 Seegene
  • 6.121 Sequencing.com
  • 6.122 Siemens Healthineers
  • 6.123 simfo GmbH
  • 6.124 Singlera Genomics Inc.
  • 6.125 SkylineDx
  • 6.126 Stratos Genomics
  • 6.127 Sure Genomics, Inc.
  • 6.128 Sysmex
  • 6.129 Sysmex Inostics
  • 6.130 Tempus Labs, Inc.
  • 6.131 Thermo Fisher Scientific Inc.
  • 6.132 Veritas Genetics
  • 6.133 Volition

7 The Global Market for Whole Genome Sequencing

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Application - Overview
    • 7.2.1 Table - Global Market by Application
    • 7.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Application - Base Year
    • 7.2.4 Chart - Global Market by Application - Final Year
    • 7.2.5 Chart - Global Market by Application - Share by Year
    • 7.2.6 Chart - Global Market by Application - Segment Growth
  • 7.3 Global Market by Organism - Overview
    • 7.3.1 Table - Global Market by Organism
    • 7.3.2 Chart - Global Market by Organism - Base/Final Year Comparison
    • 7.3.3 Chart - Global Market by Organism - Base Year
    • 7.3.4 Chart - Global Market by Organism - Final Year
    • 7.3.5 Chart - Global Market by Organism - Share by Year
    • 7.3.6 Chart - Global Market by Organism - Segment Growth
  • 7.4 Global Market by Product - Overview
    • 7.4.1 Table - Global Market by Product
    • 7.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 7.4.3 Chart - Global Market by Product - Base Year
    • 7.4.4 Chart - Global Market by Product - Final Year
    • 7.4.5 Chart - Global Market by Product - Share by Year
    • 7.4.6 Chart - Global Market by Product - Segment Growth

8 Global Whole Genome Sequencing Markets - by Application

  • 8.1 Research
    • 8.1.1 Table Research - by Country
    • 8.1.2 Chart - Research Growth
  • 8.2 Clinical Human
    • 8.2.1 Table Clinical Human - by Country
    • 8.2.2 Chart - Clinical Human Growth
  • 8.3 Clinical Tumor
    • 8.3.1 Table Clinical Tumor - by Country
    • 8.3.2 Chart - Clinical Tumor Growth
  • 8.4 Clinical Pathogen
    • 8.4.1 Table Clinical Pathogen - by Country
    • 8.4.2 Chart - Clinical Pathogen Growth
  • 8.5 Direct to Consumer
    • 8.5.1 Table Direct to Consumer - by Country
    • 8.5.2 Chart - Direct to Consumer Growth
  • 8.6 Agriculture/Other
    • 8.6.1 Table Agriculture/Other - by Country
    • 8.6.2 Chart - Agriculture/Other Growth

9 Global Whole Genome Sequencing Markets - by Organism

  • 9.1 Human
    • 9.1.1 Table Human - by Country
    • 9.1.2 Chart - Human Growth
  • 9.2 Pathogen
    • 9.2.1 Table Pathogen - by Country
    • 9.2.2 Chart - Pathogen Growth
  • 9.3 Other Organism
    • 9.3.1 Table Other Organism - by Country
    • 9.3.2 Chart - Other Organism Growth

10 Global Whole Genome Sequencing Markets - by Product

  • 10.1 Instruments
    • 10.1.1 Table Instruments - by Country
    • 10.1.2 Chart - Instruments Growth
  • 10.2 Reagents
    • 10.2.1 Table Reagents - by Country
    • 10.2.2 Chart - Reagent Growth
  • 10.3 Analysis
    • 10.3.1 Table Analysis - by Country
    • 10.3.2 Chart - Analysis Growth
  • 10.4 Software & Other
    • 10.4.1 Table Software & Other - by Country
    • 10.4.2 Chart - Software & Other Growth

11 Vision of the Future of Whole Genome Sequencing

12 Appendices

  • 12.1 United States Medicare System: January 2021 laboratory Fees Schedule
  • 12.2 The Whole Genome Sequence of SARS-CoV-2
  • 12.3 Methodology
    • 12.3.1 Authors
    • 12.3.2 Sources
Back to Top
전화 문의
F A Q